HCV and acute rejection after kidney transplantation

HCV and acute rejection after kidney transplantation describes a clinically important but contradictory relationship. HCV infection may alter recipient immunity in ways that reduce acute rejection, yet many HCV-positive recipients also carry independent immunological risks that can increase rejection. The resulting evidence is heterogeneous: some cohorts report less acute rejection, while others report similar or greater rates, including antibody-mediated rejection. The relationship therefore cannot be interpreted through viral immune suppression alone; it must be read alongside dialysis exposure, previous transplantation, transfusions, sensitization, and chronic graft injury.

Biological Basis and Clinical Setting

HCV is treated in the nephrology literature as a systemic infection rather than a disease confined to the liver. It can affect renal tissues and immune regulation, and it remains clinically relevant across chronic kidney disease, dialysis, and transplantation. In kidney recipients, the infection is associated with several complications, including glomerulonephritis and new-onset diabetes after transplantation, while its possible influence on acute rejection has remained disputed.

The transplant setting makes this question unusually difficult. HCV-positive recipients often arrive at transplantation after prolonged dialysis and substantial prior medical exposure. Time on dialysis, previous transplants, and repeated blood transfusions increase the likelihood of acquiring HCV before transplantation, but the same features also indicate a heightened immunological risk profile. Thus, an apparent association between HCV and rejection may partly reflect the characteristics of the patients who are infected rather than a direct effect of the virus itself.

Evidence for Reduced or Unchanged Rejection

One line of evidence proposes that HCV infection produces a state of immune deficiency. In kidney recipients, investigators have described a reduction in naive T-helper lymphocytes and altered proliferative responses of T lymphocytes to mitogens. Such changes would be expected to weaken cellular immune responses against the allograft and, consequently, to lower the incidence of acute rejection.

Some clinical groups have reported findings consistent with that mechanism. One long-term report found an acute rejection rate of 14.5% among HCV-infected recipients followed over a 20-year period. This observation supports the possibility that the immune effects of chronic HCV infection may dampen rejection in at least some patients, although it does not establish that the virus directly protects the graft.

Other evidence has failed to show a distinctive protective effect. In a report involving 354 anti-HCV-positive kidney transplant patients, the apparent excess of antibody-mediated acute rejection disappeared after adjustment for a panel-reactive antibody level above 20%. That result indicates that recipient sensitization, rather than HCV infection as an independent variable, may account for at least part of the observed rejection burden.

Evidence for Higher Rejection Risk

Contrasting series have found an incidence of acute rejection that was similar to or greater than that in anti-HCV-negative recipients. The paradox is explainable when HCV infection is considered together with the circumstances that commonly accompany it. Long dialysis exposure, prior transplantation, and multiple transfusions are not merely historical markers of infection; they are also routes to alloimmunization and other forms of heightened transplant risk.

A comparison of recipients transplanted in two eras illustrates this interaction. Among anti-HCV-positive patients, acute rejection occurred in 25% of those transplanted between 1998 and 2002, compared with 20.6% among a cohort transplanted between 1990 and 1994, a statistically significant difference. The later cohort contained more second-transplant recipients and highly sensitized patients, providing a plausible explanation for the higher rate without requiring HCV itself to be the primary cause.

The report of increased antibody-mediated rejection similarly complicates any simple immune-suppression model. HCV-positive recipients may have impaired immune responsiveness in some respects while simultaneously possessing antibodies or prior alloimmune exposures that place the graft at risk. Viral infection and transplant immunology can therefore pull in opposite directions within the same patient: one process may blunt particular cellular responses, while another sustains antibody-mediated injury.

Graft Loss and Interpretation of the Association

The uncertainty over acute rejection matters because anti-HCV-positive recipients have been reported to experience lower death-censored graft survival. Yet the available evidence does not show that acute rejection alone explains this outcome. In a series of 435 kidney transplant patients who underwent protocol biopsies during the first six months after transplantation, subclinical acute rejection, chronic allograft nephropathy, and HCV infection were each identified as independent risk factors for graft loss.

This finding shifts the focus from a single dramatic rejection episode to cumulative, partly silent graft injury. A recipient may have HCV infection and subclinical rejection at the same time, with chronic allograft nephropathy adding a separate pathway toward graft failure. The association between HCV and graft loss consequently appears broader than the incidence of clinically recognized acute rejection. It includes chronic injury, immune-mediated damage, infection-related complications, and the underlying risk profile inherited from the pretransplant course.

The evidence also argues against using rejection rates as a solitary measure of HCV’s transplant effect. The studies differ in their recipient populations, transplant eras, immunological risk, biopsy practices, and adjustment for sensitization. Some report lower acute rejection, some higher rates, and some show that the excess disappears after accounting for panel-reactive antibodies. Taken together, these findings support a multifactorial relationship rather than a uniform HCV-driven rejection syndrome.

Management Implications

Because treatment decisions intersect with graft safety, the timing of HCV eradication is important. Screening of kidney transplant candidates should identify both anti-HCV antibodies and active viremia, with nucleic acid testing confirming active infection. Candidates with active HCV infection require assessment of liver injury, and liver biopsy was described as the gold standard during pretransplant evaluation when viremia is present. Patients with established or decompensated cirrhosis should be referred for consideration of simultaneous liver-kidney transplantation rather than managed as ordinary kidney-alone candidates.

The pretransplant period is generally the preferred opportunity for antiviral treatment. Sustained virological response before transplantation may reduce some posttransplant complications, and available evidence suggests that most patients who achieve such a response do not relapse after immunosuppression. By contrast, interferon treatment after transplantation has been associated with an increased risk of renal allograft rejection, making posttransplant eradication strategies especially consequential for graft safety.

Waiting-list surveillance is part of the same risk-management structure. Patients who are viremic when listed should undergo regular evaluation to detect progression of liver disease, while patients who achieved sustained virological response should have at least annual nucleic acid testing to confirm its durability. A positive nucleic acid test in a previously untreated or relapsed candidate can lead to hold status and hepatology referral, and progression to early or established cirrhosis can remove the patient from the kidney-only list in favor of liver-team assessment.

The central clinical lesson is therefore one of qualification rather than certainty. HCV infection may be associated with reduced acute rejection through altered cellular immunity, but it may coexist with sensitization and other factors that increase antibody-mediated or clinical rejection. Since subclinical rejection and chronic allograft nephropathy independently threaten graft survival, appropriate care requires integrated assessment of viral activity, liver disease, alloimmune risk, biopsy findings, and treatment timing rather than an assumption that HCV is either protective or uniformly harmful to the kidney allograft.